THANK YOU
for helping us transform October Into
Metastatic Breast Cancer CURES Month!!!
Together we all raised over
$100,000
To fund the pre-clinical testing of a VERY EXCITING new breast cancer drug (TEQ103) in combination with an immunotherapy (NK-92).
Metastatic Breast Cancer (MBC) is when breast cancer cells have spread to distant parts of the body to form new tumors.
It is incurable and deadly 99% of the time, but it receives the least amount of breast cancer research funding.
Thank you to all who also joined us for the Virtual Q&A's With The Researchers Who Developed TEQ103:
Dr. David Shapiro & Dr. Paul Hergenrother
of the University of Illinois
We will be sending out periodic updates from their labs to all who participated in the webinar and to those who indicated their wish for updates when they donated.
A POTENTIAL CURE FOR
METASTATIC BREAST CANCER
TEQ103 & NK-92
North Star Cancer Research Foundation launched a fundraising campaign to raise $100,000 in October 2025 to fund critical research by Dr. David Shapiro and Dr. Paul Hergenrother at University of Illinois.
This research focuses on the drug TEQ103 in combination with NK-92, a type of immune system cell that can be given as a cancer immunotherapy in clinical trials, representing a potential breakthrough treatment for metastatic breast cancer (MBC).
Metastatic Breast Cancer has proven very difficult to treat because cancer cells continue to adapt and become resistant to targeted treatments and chemotherapies. TEQ103 uniquely stimulates a response by Natural Killer cells and this combination therapy may prevent resistant cancer cells from escaping destruction.
With federal cancer research funding being slashed, outside support is urgently needed to keep advancing this work.